Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium electroporation + irreversible electroporation + pembrolizumab in pMMR metastatic colorectal cancer
2022-500045-25-00Phase 2Completed
- Sponsor
- Zealand University Hospital
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Zealand University Hospital. Primary endpoint: Safety and tolerability of Ca-EP and IRE in combination with pembrolizumab. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2022-500045-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500045-25-00.